
XORTX Announces Change to Board of Directors
CALGARY, Alberta, Aug. 28, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (CSE : XRX) (OTCQB : XRTXF) (FRANKFURT : ANU1) (the “Company” or “XORTX”) a late clinical stage pharmaceutical development company focused on kidney disease, is pleased announce that Ian Klassen will join the XORTX board of directors effective immediately.
› Read more